Second, a prospective study should be carried out to confirm if people with a low level of circulating IgG for the CD25‐MUC1‐VEGFR1 combination are more likely to develop NSCLC than those with a normal level of such autoantibodies. This evidence concerns the gene FLT1 and non-small cell lung carcinoma.